SCHEMBL757262

SCHEMBL757262

CC1(C)Oc2cc([N+](=O)[O-])ccc2N(c2ccc(F)cc2)C1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 3/20 0.60
POLB P06746 1/20 0.43
AR P10275 1/20 0.38
CACNA1B Q00975 1/20 0.38
APBA1 Q02410 1/20 0.38
KMT2A Q03164 4/20 0.38
ALDH1A1 P00352 1/20 0.38
CASP1 P29466 1/20 0.37
CASP3 P42574 1/20 0.37
CASP4 P49662 1/20 0.37
CASP7 P55210 1/20 0.37
CASP9 P55211 1/20 0.37
CASP6 P55212 1/20 0.37
MEN1 O00255 2/20 0.37
SCN2A Q99250 1/20 0.37
WDR5 P61964 1/20 0.36
PTGS1 P23219 1/20 0.36
PMM2 O15305 1/20 0.36
MPI P34949 1/20 0.36
PHOSPHO1 Q8TCT1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL754188 0.87 MAPT (0.46) NR3C2POLBKMT2AALDH1A1CASP1
SCHEMBL759695 0.86 NR3C2 (0.45) NR3C2ARKMT2AALDH1A1CASP1
SCHEMBL758117 0.84 NR3C2 (0.43) NR3C2KMT2AALDH1A1CASP1CASP3
SCHEMBL758387 0.83 NR3C2 (0.53) NR3C2POLBARCACNA1BAPBA1
SCHEMBL756076 0.83 NR3C2 (0.43) NR3C2POLBARKMT2AALDH1A1
SCHEMBL2264897 0.83 NR3C2 (0.42) NR3C2POLBKMT2AALDH1A1CASP1
SCHEMBL756905 0.82 NR3C2 (0.52) NR3C2POLBARCACNA1BAPBA1
SCHEMBL16978177 0.82 NR3C2 (0.65) NR3C2POLBARCACNA1BAPBA1
SCHEMBL757925 0.81 NR3C2 (0.45) NR3C2POLBARCACNA1BAPBA1
SCHEMBL756166 0.81 NR3C2 (0.45) NR3C2POLBARCACNA1BAPBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9751846-B2 Method for producing 1,4-benzoxazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-09-05 US disclosed
US-9751846-B2 Method for producing 1,4-benzoxazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-09-05 US disclosed
EP-3112354-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2017-01-04 EP disclosed
US-20160362385-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-12-15 US disclosed
US-20160362385-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-12-15 US disclosed
US-9409874-B2 Method for producing 1,4-benzoxazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-08-09 US disclosed
US-9409874-B2 Method for producing 1,4-benzoxazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-08-09 US disclosed
US-20150218113-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-08-06 US disclosed
US-20150218113-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-08-06 US disclosed
EP-2883870-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2015-06-17 EP disclosed
US-8188073-B2 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
EP-1984345-B9 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-21 EP disclosed
US-20110251185-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS IIJIMA TORU 2011-10-13 US disclosed
EP-1984345-B1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS MITSUBISHI TANABE PHARMA CORP (JP) 2011-08-31 EP disclosed
US-7998956-B2 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-16 US disclosed
US-20090023716-A1 Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-22 US disclosed
EP-1984345-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-10-29 EP disclosed
WO-2007089034-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218113-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND BRSK1, BRSK2, MSMO1 NR3C2 1315/4885POLB 4702/4885AR 963/4885
US-20090023716-A1 Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents NR3C2, MC2R, NR3C1 NR3C2 1/4885POLB 3875/4885AR 18/4885
US-20160362385-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND BRSK1, BRSK2, MSMO1 NR3C2 1315/4885POLB 4702/4885AR 963/4885
US-20110251185-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS NR3C2, MC2R, NR3C1 NR3C2 1/4885POLB 3875/4885AR 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.